These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

467 related items for PubMed ID: 26349751

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B, Levan K, Partheen K, Sundfeldt K.
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R, Sideri M.
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China.
    Xu Y, Zhong R, He J, Ding R, Lin H, Deng Y, Zhou L, Li X, Jiang J, Bao Y, Luo X, Duan C.
    Clin Biochem; 2016 Jan; 49(1-2):32-40. PubMed ID: 26285075
    [Abstract] [Full Text] [Related]

  • 11. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
    Wang Z, Tao X, Ying C.
    Dis Markers; 2019 Jan; 2019():6241743. PubMed ID: 31737130
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
    Gąsiorowska E, Michalak M, Warchoł W, Lemańska A, Jasiński P, Spaczyński M, Nowak-Markwitz E.
    Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
    [Abstract] [Full Text] [Related]

  • 15. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
    Cho HY, Park SH, Park YH, Kim HB, Kang JB, Hong SH, Kyung MS.
    J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
    [Abstract] [Full Text] [Related]

  • 16. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
    Zheng H, Gao Y.
    Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
    [Abstract] [Full Text] [Related]

  • 17. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
    Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D, Australian Ovarian Cancer Study Group, Obermair A.
    Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.